Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 6, 2020- Phase II placebo-controlled study will assess the safety and efficacy of CSL312 for the treatment of patients with severe respiratory distress due to COVID-19 related pneumonia
KING OF PRUSSIA, Pa. – 6 July 2020 – Global biotherapeutics leader CSL Behring today announced that the first patient has been enrolled in its Phase 2 study to assess the safety and efficacy...
-
Jun 24, 2020• Unique gene therapy has the potential to be one of the first to market treatments to provide potentially long-term benefits with only one dose
KING OF PRUSSIA, Pa., – 24 June 2020 – Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire exclusive global license rights to commercialize an...
-
Jun 19, 2020
PHILADELPHIA--(June 19, 2020) – The University City Science Center announces the election of two new Board members, following the 2020 Annual Meeting of Shareholders held on June 19th: Yi Deng,...
-
Jun 12, 2020Global bleeding disorders community will connect and discuss treatment advances June 14-19, 2020
KING OF PRUSSIA, Pa - June 12 2020 - Global biotherapeutics leader CSL Behring announced today that the company will both attend and sponsor the World Federation of Hemophilia (WFH) first ever...
-
Jun 8, 2020
This news release is intended for medical, pharmaceutical industry and business media Maidenhead, UK 08 Jun 2020 The European Commission has today given regulatory approval for the first...
-
Jun 8, 2020Investigational Monoclonal Antibody Granted U.S. FDA Orphan Drug Designation
HATTERSHEIM, Germany – 8 June 2020 – CSL Behring, a global biotherapeutics leader, today announced results of a Phase 2 clinical trial for garadacimab (previously known as CSL312), an...
-
Jun 8, 2020• Builds on CSL Behring’s promise and commitment to the transplant community
KING OF PRUSSIA, Pa. – 8 June 2020 – Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire Vitaeris Inc., a clinical-stage biotechnology company focused on...
-
Jun 5, 2020
Oslo, Melbourne and Brisbane 05 Jun 2020 CSL appointed Trusted Manufacturer for University of Queensland’s “molecular clamp” enabled COVID-19 vaccine candidate CEPI and CSL will share costs...
Jun 2, 2020Initially, the alliance will develop treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome (WAS) and X-linked Agammaglobulinemia (XLA)SEATTLE and KING of PRUSSIA, Pa. – June 02, 2020 - Seattle Children’s Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL...
-
Jun 1, 2020
Applications are now open for the 2021 CSL Centenary Fellowships, which are offered to outstanding mid-career scientists seeking to undertake world-class medical research at an Australian academic...